CA125 modified by PLT and NLR improves the predictive accuracy of adenomyosis-derived pelvic dense adhesion

Caixia Jiang, Postgraduate\textsuperscript{a}, Chao Liu, Postgraduate\textsuperscript{a}, Jing Guo, MD, PhD\textsuperscript{a}, Li Chen, Postgraduate\textsuperscript{a}, Ning Luo, Postgraduate\textsuperscript{a}, Xiaoyan Qu, Postgraduate\textsuperscript{a}, Weihong Yang, MD, PhD\textsuperscript{b}, Qing Ren, MD, PhD\textsuperscript{b}, Zhongping Cheng, MD, PhD\textsuperscript{a,}\textsuperscript{c,}\textsuperscript{∗}

Abstract
To explore the value of serum levels of CA125, platelet count (PLT), neutrophil–lymphocyte ratio (NLR), and modified CA125 markers CA125\textsubscript{a} and CA125\textsubscript{b} in predicting pelvic dense adhesion (PDA) associated with adenomyosis, CA125\textsubscript{a} = \lg(\text{CA125} \times \text{PLT} \times 10\textsuperscript{9}), CA125\textsubscript{b} = \lg(\text{CA125} \times \text{NLR}).

This retrospective study included 304 patients who underwent surgery for adenomyosis. Correlations of serum levels of CA125, PLT, NLR, and modified CA125 markers with adenomyosis-derived PDA were analyzed by Logistic regression. Receiver operating characteristic curve was applied to assess the utility of these parameters for predicting PDA. All the parameters including CA125, PLT, NLR, and modified CA125 markers were positively correlated with PDA (\(P < .05\) or \(P < .01\)). More importantly, CA125\textsubscript{a} was more specific (85.03\% vs. 83.00\%) and more sensitive (47.56\% vs. 47.47\%) than CA125 alone for the prediction of PDA, and CA125\textsubscript{b} could also improve the predictive specificity of PDA (83.13\% vs. 47.47\%). Serum CA125, PLT, and NLR were all closely correlated with PDA in adenomyosis patients. CA125 modified by PLT and NLR could further improve the predictive accuracy of adenomyosis-derived PDA, thus providing more meaningful references for better-informed decisions about the mode of surgical access for the clinical treatment of adenomyosis.

Abbreviations: AUC = area under the curve, CI = confidence interval, NLR = neutrophil–lymphocyte ratio, OR = odds ratio, PBAC = pictorial blood loss assessment chart, PDA = pelvic dense adhesion, PLT = platelet count, ROC = receiver operating characteristic, VAS = visual analog scale.

Keywords: adenomyosis, CA125, neutrophil–lymphocyte ratio, pelvic dense adhesion, platelet count

1. Introduction
Adenomyosis is a common gynecologic condition that is characterized by the presence of heterotopic endometrial glands and stroma within the myometrium and is closely related to endometriosis. The mean occurrence of adenomyosis at hysterectomy is 20\% to 30\%. Dysmenorrhea, menorrhagia, and subfertility are the most commonly reported symptoms that heavily affect the quality of life in patients with adenomyosis.\textsuperscript{[1,2]} Hysterectomy is the current standard treatment for symptomatic adenomyosis.\textsuperscript{[3]} However, adenomyosis-derived pelvic dense adhesion (PDA) is correlated with the quality of the perioperative period directly.\textsuperscript{[4]} Recent data from patients who underwent laparoscopic hysterectomy showed that patients who required extensive adhesiolysis had a significantly increased odds ratio (OR) of 2.22 for conversion to laparotomy, and 3.5 for short-term postoperative complications (pelvic peritonitis, hematoma requiring surgical intervention, postoperative bleeding, and reoperation due to adhesions) relative to patients without adhesiolysis.\textsuperscript{[5]} The pathological changes in pelvic cavity of adenomyosis are so complicated and at high risk of suffering from tissue and organ damage that making an accurate preoperative assessment on the presence or absence of PDA in adenomyosis patients has positive guiding significance for gynecologic surgeons. It is therefore necessary to seek a noninvasive, effective, and mature alternative for the clinical diagnosis of PDA.

Serum CA125, platelet (PLT), neutrophil (NEU), and neutrophil–lymphocyte ratio (NLR) are the common blood parameters that have been used for the auxiliary diagnosis of endometriosis.\textsuperscript{[6,7]} Many studies have found that PLT and NEU can be applied to the diagnosis of clinical stages and prediction of diseases prognosis in tumors and endometriosis, and that their combination with CA125 could improve the diagnostic and predictive value.\textsuperscript{[8–10]} However, the data published so far are limited and there has been little discussion about the correlation of CA125, PLT, and NLR with adenomyosis-derived PDA.
The aim of this retrospective study was to investigate the correlation of serum levels of CA125, PLT, NLR, and modified CA125 markers with adenomyosis-derived PDA, and explore their clinical value for the prediction of PDA in 304 patients who underwent surgery for adenomyosis.

2. Materials and methods

2.1. Ethics statement

The study was approved by the Institutional Review Board of the Yangpu Hospital, Tongji University School of Medicine, Shanghai, China. Written informed consent was obtained from all subjects participating in the study.

2.2. Participants

From January 1, 2010 to March 31, 2016, 304 consecutive patients who underwent either laparoscopic or laparotomic surgery for adenomyosis at the Gynecological Department of Yangpu Hospital were included in this study. The diagnosis was confirmed by histology. Before surgery, the patients were interviewed personally using a standard questionnaire with respect to the sociodemographic characteristics, menstrual and obstetrical histories, medical complications, histories of abdominal surgery, clinical symptoms and signs, and surgical data. Participants with regular menstrual cycles (28–32 days) were not administered any hormonal therapy including oral contraceptive pills, progestins, gonadotropin-releasing hormone agonist, or levonorgestrel intrauterine system (LNG-IUS) within recent 3 months. Patients with cancer, autoimmune diseases, pelvic inflammatory disease, and other infectious diseases were excluded.

2.3. Evaluation of clinical symptoms and signs

The severity of dysmenorrhea was assessed using the visual analog scale (VAS) system as follows: 0, no pain; 1 to 3, minimal pain; 4 to 6, moderate pain; 7 to 9, severe pain; 10, the worst pain imaginable. Menstrual blood loss was evaluated using the pictorial blood loss assessment chart (PBAC). Menorrhagia was defined as excessive menstrual blood loss > 80 mL (PBAC > 100) per period. The uterine volume was measured by transvaginal ultrasound and calculated by the prolate ellipse equation: uterine volume = (π/6) × D1 × D2 × D3, where D1, D2, and D3 represent the vertical, transverse, and anteroposterior diameter of the uterus, respectively.1

2.4. Surgical information

Perioperative information was recorded. Based on the literature data and the intraoperative real-time observation, the adenomyosis-derived PDA was defined as follows: The adenomyosis lesion was invasively adhered to the surrounding tissue or organ, such as the rectum, sigmoid colon, utero-sacral ligament, cardinal ligament, and bladder, forming a dense adherent zone, from which some coffee-colored secretion flowed out when pelvic adhesiolysis was performed in most cases. Adenomyosis was complicated with chocolate cyst of ovary and peritoneal endometriosis, leading to adhesion between the cyst and the ovarian fossa. The following types of adhesion were excluded: Adhesions caused by previous pelvic and abdominal surgeries such as cesarean section and appendix surgery performed between the incision and the peritoneum or abdominal wall; these adhesions were usually thin and membranous. Adhesions caused by infectious diseases of the fallopian tube or ovary such as hydrosalpinx, thickening of the tubal wall, annex abscess, and pelvic fluid. Two surgeons responsible for the operation would complete a postoperative questionnaire about the presence or absence of PDA by visual inspection.

2.5. Determination of blood parameters

Surgery was performed during the proliferative phase of menstrual cycle in all patients, and all blood analyses were done during the early proliferative phase. Complete blood count parameters were measured by Sysmex XE-2100 Automated Hematology Analyzer (China Pharmaceutical Group Shanghai Medical Instrument Co, Ltd, Shanghai, China). The NLR was obtained by dividing the absolute neutrophil count by the absolute lymphocyte count. Serum CA125 levels were detected with CA125 diagnostic kit (Beckman Coulter Commercial Enterprise (China) Co, Ltd, Shanghai, China) using DxI UniCel 800 automated chemiluminescence immunoassay system, with the concentrations expressed as U/mL. Modified CA125 markers: CA125a = lg(CA125 × PLT × 10³); CA125b = lg(CA125 × NLR).

2.6. Statistical analysis

All statistical analyses were performed with SPSS version 16.0 for Windows (SPSS Inc, Chicago, IL). Group measures were presented as means ± standard deviations, and intragroup differences were investigated using Student t test. Categorical variables were expressed as the number of cases and percentages. Differences between categorical data were evaluated using the Chi-squared test or Fisher exact test when necessary. Correlations of variables for each group were determined using Pearson correlation coefficient or the nonconditional Logistic regression when necessary. The optimal cutoff points of CA125, PLT, NLR, and modified CA125 markers in predicting PDA were evaluated by receiver operating characteristic (ROC) analyses by calculating the area under the curve (AUC), giving the maximum sum of sensitivity and specificity for the significance test. A value of P ≤ .05 (2-sided test) was considered statistically significant.

3. Results

3.1. Comparison of characteristics between the non-PDA group and PDA group

A total of 304 adenomyosis patients were enrolled in the study, and the mean history of adenomyosis was 13.69 ± 5.32 (1–240) months. The sociodemographic, clinical, and laboratory characteristics of the groups are given in Table 1. There were no statistically significant differences in age, body mass index, parity, abortion, medical complications, history of abdominal surgery, dysmenorrhea, menstrual capacity, volume of the uterus, and the surgical modality. The patients with PDA had significantly higher estimated blood loss, a higher rate of hysterectomy and hemorrhage ≥ 500 mL, and a longer postoperative hospital stay than non-PDA patients (P < .05 or P < .05). The mean serum levels of CA125, PLT, NLR, CA125a, and CA125b in PDA group were also significantly higher than those in non-PDA group (P < .05 or P < .05).

Other than uterine injury (n = 2), bowel injury (n = 5), and bladder injury (n = 2) were the primary intraoperative complications in this study. No case was converted from laparoscopy to laparotomy. Common types of PDA found during operation were...
follows: adhesion of the posterior uterine wall and the rectum, or sigmoid colon, resulting in complete or partial closure of the Douglas pouch; fibrosis and thickening of the uterosacral ligament, cardinal ligament, and parametrial tissue; adhesion of the ovarian fossa and the ovary, or oviduct. Various types of PDA occurred in 144 (43.37%) of the 304 included cases of adenomyosis.

3.2. Correlations between the parameters and PDA

Data analysis revealed that all the parameters including CA125, PLT, NLR, CA125a, and CA125b were positively correlated with PDA (P < .05 or P < .01) (Table 2).

### Table 1

Comparison of characteristics between non-PDA and PDA groups.

| Parameter                      | Non-PDA (n = 160) | PDA (n = 144) | P  |
|--------------------------------|-------------------|---------------|----|
| Age, y                        | 43.47 ± 6.09      | 42.44 ± 5.70  | .132|
| BMI, kg/m²                     | 23.32 ± 2.89      | 23.50 ± 2.28  | .811|
| Parity (n)                     | 1 (0–8)           | 1 (0–8)       | .108|
| Abortion (n)                   | 2 (0–8)           | 1 (0–8)       | .191|
| Medical complication†, n (%)   | 20 (12.50)        | 17 (11.81)    | .863|
| Previous abdominal surgery, n (%) | 15 (9.38)     | 15 (10.42)    | .908|
| General surgery                | 42 (26.29)        | 40 (27.78)    | .396|
| Cesarean section               | 46 (28.75)        | 39 (27.08)    | .308|
| Dysmenorrhea, n (%)            | 84 (52.50)        | 79 (54.86)    | .730|
| Menorrhagia                    | 76 (47.50)        | 65 (45.14)    | .730|
| Volume of uterus, cm³          | 227.93 ± 193.51   | 234.64 ± 144.68 | .735|
| Operation type, n (%)          | 148 (92.50)       | 129 (89.58)   | .423|
| Laparotomy                     | 12 (7.50)         | 15 (10.42)    | .308|
| Hemorrhage ≥ 500 mL, n (%)     | 1 (0.63)          | 11 (7.64)     | .002|
| Postoperative hospital stay, d | 6.30 ± 2.62       | 8.67 ± 8.39   | .001|
| CA125, U/mL                    | 77.27 ± 83.26     | 136.90 ± 144.61 | .000|
| PLT, x10⁹/L                    | 264.18 ± 84.39    | 285.86 ± 86.37 | .028|
| NLR                            | 2.09 ± 0.83       | 2.34 ± 1.18   | .015|
| CA125a                         | 13.06 ± 0.49      | 13.39 ± 0.46  | .000|
| CA125b                         | 10.95 ± 0.49      | 11.26 ± 0.44  | .000|

BMI = body mass index, CA125a = lg (CA125 × PLT × 10⁹), CA125b = lg (CA125 × NLR), NLR = neutrophil–lymphocyte ratio, PDA = pelvic dense adhesion, PLT = platelet count.

† Mainly hypertension and diabetes were included.

### Table 2

Correlations between the parameters and PDA.

| Parameter | β | OR | 95% CI | P  |
|-----------|---|----|--------|----|
| CA125     | 0.005 | 1.005 | 1.003–1.008 | .000|
| PLT       | 0.003 | 1.003 | 1.000–1.006 | .030|
| NLR       | 0.289 | 1.335 | 1.055–1.690 | .024|
| CA125a    | 1.422 | 4.145 | 2.471–6.962 | .000|
| CA125b    | 1.552 | 4.719 | 2.749–8.102 | .000|

CI = confidence interval, NLR = neutrophil–lymphocyte ratio, OR = odds ratio, PDA = pelvic dense adhesion, PLT = platelet count.

4. Discussion

As a common pathological change of the pelvic cavity, adenomyosis-derived PDA is closely related to dysmenorrhea, chronic pelvic pain, and subfertility of adenomyosis.[12] Of the 304 adenomyosis patients reviewed retrospectively in this study, 144 (47.37%) cases developed various types of PDA. Adenomyosis-derived PDA interferes with visualization of the surgical filed and identification of the anatomical structure, thus lowering the quality of the perioperative period, and increasing the risk of intraoperative complications such as injury to the pelvic vessel, bladder, ureter and bowel, and postoperative complications such as bowel obstruction, chronic pelvic pain, and PDA recurrence.[5] A large sample-size study[4] on gynecologic laparoscopy reported that pelvic adhesions occurred in 61.6% cases in conversion-to-laparotomy group versus 47.7% in nonconversion group, and that they were significantly associated with an increased risk of laparotomy (OR: 2.30, 95% CI: 1.37–3.76). Adhesions were...
SN = study suggest that both of PLT and NLR may be related to the blood loss, a higher rate of hemorrhage showed that PDA patients had significant correlations between PLT and NLR and PDA in this study. It was found that either CA125 or PLT alone could be employed as an independent factor to predict PDA, but not NLR. CA125 modulated by PLT and NLR could increase the predictive accuracy of PDA. These findings may help further improve the predictive accuracy of adenomyosis-derived PDA, thus providing more meaningful references for better-informed decisions about the mode of surgical access for the clinical treatment of adenomyosis.

**Acknowledgments**

The authors thank all of the patients and families who participated in this study.

**References**

[1] Struble J, Reid S, Bedawy MA. Adenomyosis: a clinical review of a challenging gynecologic condition. J Minim Invasive Gynecol 2016;23:164-85.

[2] Guo J, Chen L, Luo N, et al. LPS/TLR4-mediated stromal cells acquire an invasive phenotype and are implicated in the pathogenesis of adenomyosis. Sci Rep 2016;6:21416.

[3] Benagiano G, Brosens I, Habiba M. Structural and molecular features of the endometriomyometrium in endometriosis and adenomyosis. Hum Reprod Update 2014;20:386-402.

[4] Sokol AI, Chuang K, Milad MP. Risk factors for conversion to laparotomy during gynecologic laparoscopy. J Am Assoc Gynecol Laparosc 2003;10:469-73.

[5] Wallwiener M, Taran F, Rothmund R, et al. Laparoscopic supracervical hysterectomy (LSH) versus total laparoscopic hysterectomy (TLH): an implementation study in 1,952 patients with an analysis of risk factors for conversion to laparotomy and complications, and of procedure-specific re-operations. Arch Gynecol Obstet 2013;288:1329-39.

**Table 1**

| CA125 | PLT | NLR | CA125a | CA125b |
|-------|-----|-----|--------|--------|
| 0.678 (0.618–0.738) | 0.574 (0.510–0.639) | 0.549 (0.484–0.614) | 0.684 (0.625–0.744) | 0.700 (0.641–0.759) |
| 83.00 | 64.71 | 30.56 | 85.03 | 81.94 |
| 47.47 | 48.10 | 80.00 | 47.56 | 53.13 |
| 56.08 | 54.70 | 57.89 | 59.24 | 61.14 |
| 74.26 | 58.46 | 56.14 | 78.00 | 76.58 |
| 64.95 | 65.27 | 56.58 | 65.27 | 66.78 |
| 41.45 | 246.50 | 2.52 | 13.00 | 10.96 |
| .000 | .025 | .138 | .000 | .000 |

AUC = area under the curve, CI = confidence interval, NLR = neutrophil-lymphocyte ratio, PPV = negative predictive value, PDA = pelvic dense adhesion, PLT = platelet count, PPV = positive predictive value, SN = sensitivity, SP = specificity.

*(Receiver operating characteristic analyses.)*
[6] Kil K, Chung JE, Pak HJ, et al. Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma. Eur J Obstet Gynecol Reprod Biol 2015;185:131–5.

[7] Tokmak A, Yildirim G, Öztas E, et al. Use of neutrophil-to-lymphocyte ratio combined with CA-125 to distinguish endometriomas from other benign ovarian cysts. Reprod Sci 2016;23:795–802.

[8] Watrowski R, Heinze G, Jäger C, et al. Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors. Tumor Biol 2016;37:12079–87.

[9] Templeton AJ, McNamara MG, Eruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.

[10] Yavuzcan A, Caglar M, Ustun Y, et al. Evaluation of mean platelet volume, neutrophil-lymphocyte ratio and platelet/lymphocyte ratio in advanced stage endometriosis with endometrioma. J Turk Ger Gynecol Assoc 2013;14:210–5.

[11] Liu M, Cheng Z, Dai H, et al. Long-term efficacy and quality of life associated with laparoscopic bilateral uterine artery occlusion plus partial resection of symptomatic adenomyosis. Eur J Obstet Gynecol Reprod Biol 2014;176:20–4.

[12] Li X, Liu X, Guo S. Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy. J Obstet Gynaecol Res 2014;40:485–94.

[13] Leonard F, Chopin N, Borghese B, et al. Total laparoscopic hysterectomy: preoperative risk factors for conversion to laparotomy. J Minim Invasive Gynecol 2005;12:312–7.

[14] Liu X, Shen M, Qi Q, et al. Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast trans-differentiation in the development of adenomyosis. Hum Reprod 2016;31:734–49.

[15] Berkes E, Oehmke F, Tinneberg H, et al. Association of neutrophil extracellular traps with endometriosis-related chronic inflammation. Eur J Obstet Gynecol Reprod Biol 2014;183:193–200.

[16] Cheng YM, Wang ST, Chou CY. Serum CA-125 in preoperative patients at high risk for endometriosis. Obstet Gynecol 2002;99:375–80.

[17] Bodur S, Dundar O, Pektas MK, et al. The clinical significance of classical and new emerging determinants of adenomyosis. Int J Clin Exp Med 2015;8:7958–64.

[18] Takamura M, Koga K, Izumi G, et al. Neutrophil depletion reduces endometriotic lesion formation in mice. Am J Reprod Immunol 2016;76:193–8.

[19] Cho S, Cho H, Nam A, et al. Neutrophil-to-lymphocyte ratio as an adjunct to CA-125 for the diagnosis of endometriosis. Fertil Steril 2008;90:2073–9.

[20] Kabawat SE, Bast RJ, Bhan AK, et al. Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983;2:273–85.

[21] Kim SK, Park JY, Jee BC, et al. Association of the neutrophil-to-lymphocyte ratio and CA125 with the endometriosis score. Clin Exp Reprod Med 2014;41:151–7.